CN117479955A - 允许免疫细胞浸润到肿瘤中的方法 - Google Patents

允许免疫细胞浸润到肿瘤中的方法 Download PDF

Info

Publication number
CN117479955A
CN117479955A CN202180099369.0A CN202180099369A CN117479955A CN 117479955 A CN117479955 A CN 117479955A CN 202180099369 A CN202180099369 A CN 202180099369A CN 117479955 A CN117479955 A CN 117479955A
Authority
CN
China
Prior art keywords
cancer
subject
metastatic
binding fragment
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180099369.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·菲利翁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alethia Biotherapeutics ULC
Original Assignee
Alethia Biotherapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alethia Biotherapeutics ULC filed Critical Alethia Biotherapeutics ULC
Publication of CN117479955A publication Critical patent/CN117479955A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202180099369.0A 2021-04-27 2021-04-27 允许免疫细胞浸润到肿瘤中的方法 Pending CN117479955A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2021/050572 WO2022226623A1 (en) 2021-04-27 2021-04-27 Method for allowing immune cells infiltration in tumors

Publications (1)

Publication Number Publication Date
CN117479955A true CN117479955A (zh) 2024-01-30

Family

ID=83846453

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180099369.0A Pending CN117479955A (zh) 2021-04-27 2021-04-27 允许免疫细胞浸润到肿瘤中的方法
CN202280042256.1A Pending CN117479956A (zh) 2021-04-27 2022-04-26 允许免疫细胞浸润到肿瘤中的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202280042256.1A Pending CN117479956A (zh) 2021-04-27 2022-04-26 允许免疫细胞浸润到肿瘤中的方法

Country Status (10)

Country Link
US (2) US20240199758A1 (https=)
EP (2) EP4329801A4 (https=)
JP (2) JP2024516416A (https=)
KR (2) KR20240014052A (https=)
CN (2) CN117479955A (https=)
AU (2) AU2021442702A1 (https=)
CA (2) CA3173786A1 (https=)
IL (2) IL307954A (https=)
MX (2) MX2023012766A (https=)
WO (2) WO2022226623A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118914553A (zh) * 2024-07-22 2024-11-08 西安医学院第一附属医院 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors
MX2024009671A (es) * 2022-02-07 2024-08-19 Alethia Biotherapeutics Inc Terapia de combinación para uso en el tratamiento del cáncer de pulmón de células no pequeñas.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1882A (en) 1872-12-11 Angus. Campbell A towel hanger
ES2543341T3 (es) 2005-09-13 2015-08-18 National Research Council Of Canada Métodos y composiciones para modular la actividad de células tumorales
EA034462B1 (ru) 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
US9822170B2 (en) * 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118914553A (zh) * 2024-07-22 2024-11-08 西安医学院第一附属医院 一种结直肠腺瘤和结直肠癌早期筛查的生物标志物的应用

Also Published As

Publication number Publication date
AU2021442702A1 (en) 2023-11-30
KR20240013743A (ko) 2024-01-30
WO2022226637A1 (en) 2022-11-03
EP4329801A1 (en) 2024-03-06
IL307961A (en) 2023-12-01
CA3173786A1 (en) 2022-10-27
EP4329802A1 (en) 2024-03-06
IL307954A (en) 2023-12-01
CA3173797A1 (en) 2023-10-05
AU2022266854A9 (en) 2023-12-07
JP2024516416A (ja) 2024-04-15
AU2022266854A1 (en) 2023-11-30
KR20240014052A (ko) 2024-01-31
EP4329802A4 (en) 2025-09-03
EP4329801A4 (en) 2025-05-14
JP2024516818A (ja) 2024-04-17
MX2023012766A (es) 2024-02-23
US20240199758A1 (en) 2024-06-20
WO2022226623A1 (en) 2022-11-03
CN117479956A (zh) 2024-01-30
US20240317884A1 (en) 2024-09-26
MX2023012768A (es) 2023-11-13

Similar Documents

Publication Publication Date Title
US20210040216A1 (en) Methods of treating her2-positive cancer
KR20200112867A (ko) 길항적 항-pd-1 항체로 암을 치료하는 방법
CN110167594A (zh) 皮下her2抗体配制剂
TW202233239A (zh) 用於治療非小細胞肺癌之抗b7-h1及抗ctla-4抗體
JP2022180472A (ja) 癌のための併用療法
CN117479955A (zh) 允许免疫细胞浸润到肿瘤中的方法
CN114340679A (zh) 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物
BR112020025452A2 (pt) Tratamento de nsclc de estágio iii e mitigação de condição patológicas associadas com o tratamento
US20260092112A1 (en) Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma
JP2022512866A (ja) がんを処置するための抗ｌａｇ３抗体の投薬レジメンおよび抗ｐｄ－１抗体との組み合わせ治療
TW202207976A (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
WO2024137776A1 (en) Combination therapy for lung cancer
CN119997973A (zh) 使用间充质上皮转化因子（met）靶向剂治疗非小细胞肺癌的方法
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法
CN118900700A (zh) 用于治疗非小细胞肺癌的联合疗法
TW202523693A (zh) 手術前後基於抗ｐｄ－１之治療
WO2023164662A1 (en) Treatment of squamous non small cell lung cancer
WO2025087358A1 (zh) 抗体药物偶联物用于治疗癌症的方法
WO2026039321A1 (en) Methods for treating prostate cancer
CN121969389A (zh) 用于治疗癌症的联合疗法
CN119630418A (zh) 抗GARP-TGF-β1/PD-1组合疗法
HK40101387A (zh) 联合抗her2抗体和化疗剂治疗胃癌的用途
CN120204383A (zh) 抗pd-1抗体联合化疗剂在治疗肿瘤中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: Canada

Address after: CANACONA GA IN

Applicant after: Alesya Biotherapeutics LLC

Address before: Kaisan ohokkatsu

Applicant before: ALETHIA BIOTHERAPEUTICS Inc.

Country or region before: Canada

CB02 Change of applicant information